Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 14, 2024 08:30 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

HOUSTON, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) announces the appointment of Carolyn Shelton as Senior Vice President of...
September 05, 2024 09:00 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

HOUSTON, TX, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) announced its participation in a high-profile Congressional roundtable in...
July 18, 2024 08:30 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

‘Breaking Barriers’ Coalition Formed to Address Opioid Use Disorder in the USA Nexalin CEO Mark White Participates in Inaugural Meeting HOUSTON, TX, July 18, 2024 (GLOBE NEWSWIRE) --...
July 01, 2024 14:45 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Announces Closing of $5.2 Million Public Offering

HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the closing of its previously announced public offering of...
June 27, 2024 21:15 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

HOUSTON, TX, June 27, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced the pricing of a public offering of 3,000,000 shares of...
June 26, 2024 09:00 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

Study demonstrates strong statistical separation between patients receiving Nexalin’s DIFS® technology in combination with escitalopram (Lexapro) vs sham group receiving escitalopram alone Two-thirds...
June 20, 2024 08:30 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office...
June 13, 2024 15:00 ET | Source: Nexalin Technology, Inc.

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA)...
June 04, 2024 08:30 ET | Source: Nexalin Technology, Inc.

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo...
June 03, 2024 08:30 ET | Source: Nexalin Technology, Inc.

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

HOUSTON, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announces that the U.S. Food and Drug Administration (FDA) has provided...